Loomis Sayles released its “Small Cap Value Fund” third-quarter 2025 investor letter, reporting a 6.21% return compared to 12.60% for the Russell 2000 Value Index. Strong US equity results were driven by easing tariff concerns, a pro-growth budget, and anticipation of further Federal Reserve rate cuts. Check the fund’s top five holdings for 2025 picks.

In its investor letter, Loomis Sayles Small Cap Value Fund highlighted Haemonetics Corporation (NYSE:HAE), a Boston-based medical technology company. Haemonetics Corporation (NYSE:HAE) had a one-month return of -0.92% and a 3.36% gain over the last 52 weeks. On December 24, 2025, shares closed at $80.01 with a $3.855 billion market cap.

Loomis Sayles Small Cap Value Fund noted in its third quarter 2025 letter that stock selection measures trailed the index due to a style mismatch with their high-quality approach. Haemonetics Corporation (NYSE:HAE) was mentioned as detracting from performance, along with Alight, Inc. and Kyndryl Holdings Incorporated.

Haemonetics Corporation (NYSE:HAE) is not among the 30 most popular stocks among hedge funds, with 36 portfolios holding it at the end of the third quarter. In the second quarter of fiscal 2026, the company reported a 5% revenue decline to $327 million. While Haemonetics Corporation (NYSE:HAE) shows investment potential, some believe certain AI stocks offer greater upside and less downside risk.

Read more at Yahoo Finance: Do You Believe in the Long-Term Growth Potential of Haemonetics Corporation (HAE)?